BG
AUTL

Bollard Group’s Autolus Therapeutics AUTL Stock Holding History

Bollard Group’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,276
Closed -$53K – 440
2020
Q2 		$53K Buy
+3,276
New +$36.3K ﹤0.01% 338

Other funds holding AUTL

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bollard Group's AUTL Position: Q3 2020 in Review

Bollard Group sold out of Autolus Therapeutics (AUTL) in Q3 2020, closing a stake of 3,276 shares — an estimated $53K sold.

Bollard Group first reported a position in AUTL in Q2 2020 and held it in 1 quarter. The position peaked at $53K in Q2 2020. 46 funds tracked by Wall St. Rank hold AUTL as of Q3 2020.

  • Bollard Group reported no remaining Autolus Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Bollard Group sold 3,276 Autolus Therapeutics shares in Q3 2020, an estimated $53K.
  • Bollard Group first reported a position in Autolus Therapeutics in Q2 2020 and held it in 1 quarter.
  • Bollard Group's Autolus Therapeutics position peaked at $53K in Q2 2020.
  • 46 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q3 2020.

Based on Bollard Group's 13F filing for Q3 2020, filed 12 Nov 2020.